These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

947 related items for PubMed ID: 8855806

  • 1. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A, Branca F, Spadoni GL, Cianfarani S, Pasquino AM, Argirò G, Vitale S, Robins SP, Boscherini B.
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [Abstract] [Full Text] [Related]

  • 2. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
    Högler W, Briody J, Moore B, Lu PW, Cowell CT.
    Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
    [Abstract] [Full Text] [Related]

  • 3. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
    Bollerslev J, Møller J, Thomas S, Djøseland O, Christiansen JS.
    Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
    [Abstract] [Full Text] [Related]

  • 4. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M.
    J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
    [Abstract] [Full Text] [Related]

  • 5. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH.
    Kamp GA, Zwinderman AH, Van Doorn J, Hackeng W, Frölich M, Schönau E, Wit JM.
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):315-25. PubMed ID: 12201823
    [Abstract] [Full Text] [Related]

  • 6. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ, Hamdy NA, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [Abstract] [Full Text] [Related]

  • 8. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age.
    Lieuw-A-Fa M, Sierra RI, Specker BL.
    J Bone Miner Res; 1995 Jun; 10(6):849-53. PubMed ID: 7572307
    [Abstract] [Full Text] [Related]

  • 9. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G.
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [Abstract] [Full Text] [Related]

  • 10. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
    Colmenares A, González L, Gunczler P, Lanes R.
    J Pediatr Endocrinol Metab; 2012 May; 25(7-8):651-7. PubMed ID: 23155689
    [Abstract] [Full Text] [Related]

  • 11. Urinary excretion of pyridinium crosslinks in short children treated with growth hormone.
    Branca F, Spagnoli A, Cianfarani S, Spadoni G, Golden MH, Boscherini B, Valtueña S, Robins SP.
    J Pediatr Endocrinol Metab; 2002 Jan; 15(1):27-34. PubMed ID: 11826867
    [Abstract] [Full Text] [Related]

  • 12. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
    Sartorio A, Arosio M, Conti A, Ferrero S, Porretti S, Faglia G.
    J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
    [Abstract] [Full Text] [Related]

  • 13. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [Abstract] [Full Text] [Related]

  • 15. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
    Lanes R, Gunczler P, Esaa S, Weisinger JR.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
    [Abstract] [Full Text] [Related]

  • 16. [Establishment and validation of predictive model of short term responses to recombinant human growth hormone treatment in prepubertal short stature children with various growth hormone secretary statuses].
    Su Z, Li YH, Ma HM, Chen HS, DU ML, Gu YF.
    Zhonghua Er Ke Za Zhi; 2008 Oct; 46(10):757-62. PubMed ID: 19099881
    [Abstract] [Full Text] [Related]

  • 17. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A, Rogol AD, Elsiddig S, Khalil A, Alaaraj N, Alyafie F, Ahmed H, Elawwa A.
    J Pediatr Endocrinol Metab; 2021 Oct 26; 34(10):1263-1271. PubMed ID: 34291621
    [Abstract] [Full Text] [Related]

  • 18. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
    Crofton PM, Stirling HF, Schönau E, Kelnar CJ.
    Clin Endocrinol (Oxf); 1996 Apr 26; 44(4):385-94. PubMed ID: 8706304
    [Abstract] [Full Text] [Related]

  • 19. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children.
    Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG.
    J Clin Endocrinol Metab; 2008 Feb 26; 93(2):352-7. PubMed ID: 18000092
    [Abstract] [Full Text] [Related]

  • 20. Short-term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion.
    Andersson B, Swolin-Eide D, Magnusson P, Albertsson-Wikland K.
    Clin Endocrinol (Oxf); 2015 Jan 26; 82(1):91-9. PubMed ID: 24818653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.